Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

GenFleet Therapeutics (劲方医药) Pre-IPO: Leadership in KRAS G12D Target

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Tyligand Bioscience / Equity Capital Markets

<ul>
<li>Tyligand Bioscience, a China-based biotech, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC is the sole sponsor.</li>
<li>In this note, we look at the company's one late-stage core product TSN1611.</li>
<li>We also look at the company's pre-IPO investors and management team.</li>
</ul>


Tyligand Bioscience, a China-based biotech, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC is the sole sponsor.
In this note, we look at the company's one late-stage core product TSN1611.
We also look at the company's pre-IPO investors and management team.


Tyligand Bioscience (泰励生物) Pre-IPO: Late Entrant to the KRAS G12D Target